Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7913-02: Phase 1 magrolimab + azacitidine in MDS
jRCT2031210139Phase 1Suspended
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magrolimab in myelodysplastic syndrome (MDS), sponsored by Ono Pharmaceutical. Primary endpoints: Tolerability and Safety. Started Aug 2021; status: suspended.
02
Drugs
magrolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2031210139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210139.